A randomised, double-blind, crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in patients with post-herpetic neuralgia

Trial Profile

A randomised, double-blind, crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in patients with post-herpetic neuralgia

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2014

At a glance

  • Drugs CNV 2197944 (Primary)
  • Indications Neuropathic pain; Postherpetic neuralgia
  • Focus Therapeutic Use
  • Sponsors Convergence Pharmaceuticals
  • Most Recent Events

    • 10 May 2014 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 28 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 28 Jan 2014 Planned End Date changed from 1 Apr 2014 to 1 Jun 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top